Latest news with #Mirabegron
&w=3840&q=100)
Business Standard
07-08-2025
- Business
- Business Standard
Lupin shares advance 5% after Q1 results; should you buy in?
Shares of Lupin gained nearly 5 per cent on Thursday as analysts remained bullish after the firm posted a 52 per cent year-on-year increase in net profit in the first quarter of the current financial year (Q1FY26) The pharma major's stock rose as much as 4.65 per cent during the day to ₹1,937.9 per share, the biggest intraday rise since April 28 this year. The stock pared gains to trade 3.8 per cent higher at ₹1,919 apiece, compared to a 0.32 per cent decline in Nifty 50 as of 9:57 AM. Shares of the company snapped a two-day losing streak and currently trade at 5.9 times the average 30-day trading volume, according to Bloomberg. The counter has fallen 18 per cent this year, compared to a 3.6 per cent advance in the benchmark Nifty 50. Lupin has a total market capitalisation of ₹88,332.65 crore. Lupin Q1 results The drug maker reported a profit after tax (PAT) of ₹1,221 crore in the April-June quarter, marking an increase of 72 per cent year-on-year (Y-o-Y). Revenue rose to ₹6,164 crore in the first quarter as against ₹5,514 crore in the year-ago period. The company said its sales in the US stood at ₹2,404 crore in the June quarter, registering a growth of 24 per cent as compared to ₹1,934 crore in the year-ago period. India sales for Q1 FY26 stood at ₹2,089 crore, up 8 per cent from ₹1,938 crore. "We continue to build strong business momentum, anchored by a robust product portfolio, improved efficiencies, and effective use of assets and investments," Managing Director Nilesh Gupta said. "As we begin the year, our sharpened focus on compliance, innovation, and technology positions us to further unlock sustainable growth," he added. Analysts on Lupin Q1 results Antique Stock Broking noted that Lupin delivered a strong first-quarter performance for FY26. Ebitda rose 28 per cent Y-o-Y despite a 38 per cent increase in R&D expenses. The quarter marked the launch of Tolvaptan (gJynarque) under sole FTF exclusivity in the US, boosting US sales to $282 million, it said, adding that the base US business saw single-digit price erosion. A further ramp-up is expected in the second quarter, analysts said. It maintained a 'Buy' rating on the stock with a revised target of ₹2,450 per share (earlier ₹2,395). Systematix Institutional Equities said that while revenue and Ebitda came in below expectations, net profit was in line. The revenue and Ebitda miss was primarily due to lower-than-expected US sales, it noted. The brokerage has revised its estimates to reflect a higher contribution from generic Mirabegron over the year. Systematix maintains a 'Hold' rating on Lupin with a target price of ₹2,050. Lupin's superior performance was driven by 180-day exclusivity in tolvaptan and continued running in gSpiriva and gMyrbetriq, according to analysts at Nuvama Institutional Equities. FY26 is a strong year for Lupin with further launches of glucagon and liraglutide over the next few months, it said. They retained 'Buy' with a target price of ₹2,340 per share.
Bloomberg
31-07-2025
- Business
- Bloomberg
Astellas Shares Jump After Profits Fueled by Strong Drug Sales
Astellas Pharma Inc. rose the most in more than three months after quarterly profit exceeded analysts' projections, driven by robust sales of its Padcev cancer treatment and Mirabegron used to control overactive bladders. The stock rose as much as 7.2% in early morning trading in Tokyo on Thursday, the biggest intraday gain since April 10.
Yahoo
04-06-2025
- Business
- Yahoo
Overactive Bladder Treatment Market to Reach USD 5.45 Billion by 2032, Driven by Aging Population, Drug Innovation, and Rising Awareness
According to Research by SNS Insider, U.S. Overactive Bladder Treatment Market Continues Steady Growth Amid High Prevalence of Urinary Disorders and Increased R&D Initiatives by Key Pharma Players. Austin, June 04, 2025 (GLOBE NEWSWIRE) -- Overactive Bladder Treatment Market Size & Growth Analysis: According to SNS Insider, the Overactive Bladder Treatment Market size was estimated at USD 3.63 billion in 2023 and is expected to reach USD 5.45 billion by 2032, at a CAGR of 4.64% during the forecast period of 2024-2032. The overactive bladder treatment market has been growing steadily owing to the increasing number of conditions associated with OAB and the availability of treatment modalities. It is due to rising aging populations, improved levels of diagnosis, and developing pharma treatments, which are some of the factors driving growth in the market. Furthermore, innovations in drugs are becoming safer and more potent, and the expanding access to healthcare facilities also remains a driving factor for the growth of the market a Sample Report of Overactive Bladder Treatment Market@ The U.S. overactive bladder treatment market was estimated at USD 1.05 billion in 2023 and is expected to reach USD 1.56 billion by 2032, at a CAGR of 4.53% during the forecast period of 2024-2032. The United States had the largest share in the North American overactive bladder treatment market owing to its high incidence of OAB conditions, well-developed healthcare infrastructure, and extensive presence of top pharma players. The nation is also favored by increased awareness and early detection, thus leading to higher treatment adoption. Overactive Bladder Treatment Market Report Scope Report Attributes Details Market Size in 2023 US$ 3.63 billion Market Size by 2032 US$ 5.45 billion CAGR CAGR of 4.64% From 2024 to 2032 Base Year 2023 Forecast Period 2024-2032 Historical Data 2020-2022 Key Segments By Disease Type (Neurogenic Overactive Bladder, Idiopathic Overactive Bladder)By Type (Anticholinergics, Neuromodulation, Mirabegron, Botox, Other)By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Others) Segmentation Insights By Type, Mirabegron Segment Leads the Market Mirabegron dominated the overactive bladder treatment market in 2023 with a 26% market share, as it was more potent than conventional anticholinergic medications and had a better safety profile. Mirabegron (Myrbetriq), the first β3-adrenoceptor agonist on the market, is an alternative to antimuscarinics that has fewer serious side effects (e.g., xerostomia and constipation associated with antimuscarinics). Its once-daily dosing and improved patient compliance make it easier for patients to take while also benefiting doctors. By Disease Type, Idiopathic OAB Segment dominated the Overactive Bladder Treatment Market In 2023, the idiopathic overactive bladder segment accounted for the largest share in the market with 76% market share because it is highly prevalent and has a mysterious etiology, which demands treatment. Compared to neurogenic OAB, idiopathic conditions are without any recognizable neurological reason, thus prevailing more in the general population, particularly the elderly. The increasing population of elderly individuals, coupled with lifestyle and rising awareness rates, has accelerated diagnosis rates. Since drug treatments such as Mirabegron and antimuscarinics are widely prescribed for idiopathic patients, this category is still creating significant demand for the drugs as well as urological visits. By Distribution Channel, the Retail Pharmacies Segment Dominated the Overactive Bladder Treatment Market in 2023 The retail pharmacies segment led the market by 76% market share in 2023 because it was easily accessible, convenient, and could directly reach patients. The majority of overactive bladder drugs, such as Mirabegron and antimuscarinics, are prescribed and dispensed via retail pharmacies. Retail pharmacies offer direct counseling, assist in medication adherence, and typically serve as the first point of contact for chronic disease management. Need Any Customization Research on Overactive Bladder Treatment Market, Enquire Now@ Major Players Analysis Listed in this Report are: Astellas Pharma Inc. Pfizer Inc. AbbVie Inc. Teva Pharmaceutical Industries Ltd. Medtronic Plc. Viatris Inc. Hisamitsu Pharmaceutical Co. Inc. Johnson & Johnson Endo Pharmaceuticals Inc. Alembic Pharmaceuticals Limited Axonics Modulation Technologies Inc. Apotex Inc. Aurobindo Pharma Limited Cogentix Medical Inc. Intas Pharmaceuticals Ltd. Macleods Pharmaceuticals Ltd. Mylan N.V. Sanofi Sumitomo Pharma America Inc. (Urovant Sciences) Alembic Pharmaceuticals Limited. North America Leads the Overactive Bladder Treatment Market, Asia Pacific is the Most Rapidly Growing Region North America dominates the overactive bladder treatment market with a 37% market share in 2023 due to its established healthcare infrastructure, high patient awareness, and dominant access to advanced therapeutics. The region has the development of huge pharmaceutical companies along with an increasing population of elderly adults, who are more susceptible to urological conditions. Asia Pacific is expected to observe the fastest growth in the overactive bladder treatment market during the forecast period due to growing healthcare spending, rising awareness, and an expanding geriatric population. There are lots of investments in the field of healthcare around the regions of China, India, and Japan. Buy a Single-User PDF of Overactive Bladder Treatment Market Analysis & Outlook Report 2024-2032@ About Us: SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world. CONTACT: Contact Us: Jagney Dave - Vice President of Client Engagement Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK)
